2022
Bayesian local exchangeability design for phase II basket trials
Liu Y, Kane M, Esserman D, Blaha O, Zelterman D, Wei W. Bayesian local exchangeability design for phase II basket trials. Statistics In Medicine 2022, 41: 4367-4384. PMID: 35777367, PMCID: PMC10279458, DOI: 10.1002/sim.9514.Peer-Reviewed Original ResearchRegression methods for the appearances of extremes in climate data
Yu C, Blaha O, Kane M, Wei W, Esserman D, Zelterman D. Regression methods for the appearances of extremes in climate data. Environmetrics 2022, 33 DOI: 10.1002/env.2764.Peer-Reviewed Original Research
2024
A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling
Wei W, Blaha O, Esserman D, Zelterman D, Kane M, Liu R, Lin J. A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling. Statistics In Medicine 2024, 43: 2439-2451. PMID: 38594809, PMCID: PMC11325877, DOI: 10.1002/sim.10077.Peer-Reviewed Original Research
2021
Unified exact design with early stopping rules for single arm clinical trials with multiple endpoints
Wei W, Esserman D, Kane M, Zelterman D. Unified exact design with early stopping rules for single arm clinical trials with multiple endpoints. Statistical Methods In Medical Research 2021, 30: 1575-1588. PMID: 34159859, PMCID: PMC8959087, DOI: 10.1177/09622802211013062.Peer-Reviewed Original ResearchA Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1
Weiss SA, Djureinovic D, Jessel S, Krykbaeva I, Zhang L, Jilaveanu L, Ralabate A, Johnson B, Levit NS, Anderson G, Zelterman D, Wei W, Mahajan A, Trifan O, Bosenberg M, Kaech SM, Perry CJ, Damsky W, Gettinger S, Sznol M, Hurwitz M, Kluger HM. A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1. Clinical Cancer Research 2021, 27: 4757-4767. PMID: 34140403, PMCID: PMC9236708, DOI: 10.1158/1078-0432.ccr-21-0903.Peer-Reviewed Original ResearchConceptsAnti-PD-1/PD-L1Non-small cell lung cancerCell lung cancerRenal cell carcinomaPD-L1Lung cancerDisease progressionCommon treatment-related adverse eventsPD-1/PD-L1 inhibitorsTreatment-related adverse eventsPhase 2 doseSubstantial clinical challengeUnconfirmed partial responseDose-limiting toxicityPD-L1 inhibitorsPhase I trialDose-escalation designPro-inflammatory cytokinesMultiple tumor typesAsymptomatic elevationStable diseaseIntolerable toxicityAdverse eventsMedian durationPartial response
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply